Basic Study
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 14, 2015; 21(6): 1765-1774
Published online Feb 14, 2015. doi: 10.3748/wjg.v21.i6.1765
Sirtuin 1 in rat orthotopic liver transplantation: An IGL-1 preservation solution approach
Eirini Pantazi, Mohamed Amine Zaouali, Mohamed Bejaoui, Emma Folch-Puy, Hassen Ben Abdennebi, Ana Teresa Varela, Anabela Pinto Rolo, Carlos Marques Palmeira, Joan Roselló-Catafau
Eirini Pantazi, Mohamed Amine Zaouali, Mohamed Bejaoui, Emma Folch-Puy, Joan Roselló-Catafau, Experimental Hepatic Ischemia, Reperfusion Unit, Institute of Biomedical Research of Barcelona, Barcelona, 08036 Catalonia, Spain
Mohamed Amine Zaouali, Hassen Ben Abdennebi, Faculty of Pharmacy, Molecular Biology and Anthropology Applied to Development and Health, 5000 Monastir, Tunisia
Ana Teresa Varela, Carlos Marques Palmeira, Department of Life Sciences and Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal
Anabela Pinto Rolo, Department of Biology, University of Aveiro, 3810-193 Aveiro, Portugal
Author contributions: Pantazi E and Zaouali MA designed and performed the experimental work; Pantazi E, Zaouali MA, Bejaoui M and Folch-Puy E provided protocols and analysed data; Zaouali MA and Bejaoui M established the animal experimental model; Varela AT, Rolo AP and Palmeira CM determined NAD+, NAMPT levels; Ben Abdennebi H, Palmeira CM and Roselló-Catafau J contributed to the critical analyses of the data; Pantazi E, Zaouali MA, Folch-Puy E and Roselló-Catafau J coordinated the experiments and wrote the paper; all authors have read and approved the final manuscript.
Supported by Fondo de Investigaciones Sanitarias, No. FIS PI12/00519; and Eirini Pantazi is the recipient of a fellowship from AGAUR, No. 2012FI_B00382, Generalitat de Catalunya, Barcelona, Catalonia, Spain.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Joan Roselló-Catafau, Professor, Experimental Hepatic Ischemia, Reperfusion Unit, Institute of Biomedical Research of Barcelona, IIBB-CSIC, C/ Rosselló 161, 7th floor, 08036 Barcelona, Spain. jrcbam@iibb.csic.es
Telephone: +34-93-3638300 Fax: +34-93-3638301
Received: August 5, 2014
Peer-review started: August 6, 2014
First decision: October 14, 2014
Revised: October 25, 2014
Accepted: November 7, 2014
Article in press: November 11, 2014
Published online: February 14, 2015
Processing time: 189 Days and 20.4 Hours
Abstract

AIM: To investigate the possible involvement of Sirtuin 1 (SIRT1) in rat orthotopic liver transplantation (OLT), when Institute Georges Lopez 1 (IGL-1) preservation solution is enriched with trimetazidine (TMZ).

METHODS: Male Sprague-Dawley rats were used as donors and recipients. Livers were stored in IGL-1 preservation solution for 8h at 4 °C, and then underwent OLT according to Kamada’s cuff technique without arterialization. In another group, livers were stored in IGL-1 preservation solution supplemented with TMZ, at 10-6 mol/L, for 8 h at 4 °C and then underwent OLT. Rats were sacrificed 24 h after reperfusion, and liver and plasma samples were collected. Liver injury (transaminase levels), mitochondrial damage (glutamate dehydrogenase activity) oxidative stress (malondialdehyde levels), and nicotinamide adenine dinucleotide (NAD+), the co-factor necessary for SIRT1 activity, were determined by biochemical methods. SIRT1 and its substrates (ac-FoxO1, ac-p53), the precursor of NAD+, nicotinamide phosphoribosyltransferase (NAMPT), as well as the phosphorylation of adenosine monophosphate activated protein kinase (AMPK), p-mTOR, p-p70S6K (direct substrate of mTOR), autophagy parameters (beclin-1, LC3B) and MAP kinases (p-p38 and p-ERK) were determined by Western blot.

RESULTS: Liver grafts preserved in IGL-1 solution enriched with TMZ presented reduced liver injury and mitochondrial damage compared with those preserved in IGL-1 solution alone. In addition, livers preserved in IGL-1 + TMZ presented reduced levels of oxidative stress. This was consistent with enhanced SIRT1 protein expression and elevated SIRT1 activity, as indicated by decreased acetylation of p53 and FoxO1. The elevated SIRT1 activity in presence of TMZ can be attributed to the enhanced NAMPT protein and NAD+/NADH levels. Up-regulation of SIRT1 was consistent with activation of AMPK and inhibition of phosphorylation of mTOR and its direct substrate (p-p70S6K). As a consequence, autophagy mediators (beclin-1 and LC3B) were over-expressed. Furthermore, MAP kinases were regulated in livers preserved with IGL-1 + TMZ, as they were characterized by enhanced p-ERK and decreased p-p38 protein expression.

CONCLUSION: Our study shows that IGL-1 preservation solution enriched with TMZ protects liver grafts from the IRI associated with OLT, through SIRT1 up-regulation.

Keywords: Sirtuin 1; Ischemia-reperfusion injury; Liver transplantation; IGL-1 preservation solution; Trimetazidine

Core tip: Sirtuin 1 (SIRT1) has been implicated in pathways associated with ischemia-reperfusion injury (IRI), but its role in rat orthotopic liver transplantation has not yet been established. In our study, SIRT1 protein expression levels and activity increased when Institut Georges Lopez 1 (IGL-1) preservation solution was supplemented with trimetazidine, which was associated with less hepatic injury and mitochondrial damage. The increased deacetylation of FoxO1 by SIRT1 agreed with less oxidative stress and the activation of the autophagy pathway. These findings support the notion that SIRT1 up-regulation may be an effective strategy for reducing IRI and improving liver transplantation outcome.